BridgeBio Oncology Therapeutics Inc. (BBOT) vs Scribe Therapeutics Inc. (SCTX)

A side-by-side comparison of BridgeBio Oncology Therapeutics Inc. and Scribe Therapeutics Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

BBOT

BridgeBio Oncology Therapeutics Inc.

$280M

$3.50HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

SCTX

Scribe Therapeutics Inc.

$264M

$16.33HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

Total return — BBOT vs SCTX

growth of $100 · dividends reinvested · last 1y

BBOT -58.7% (-58.7%/yr)SCTX +8.1% (+8.1%/yr)SCTX compounded faster over this window

BBOT SCTX

Metrics side by side

Total return (annualized)

Metric	BBOT	SCTX
Total return (1Y)	-70.70%	N/A

SCTX is an index fund, so valuation, profitability, and per-company growth metrics don't apply — the head-to-head here is total return (price plus reinvested dividends).

Go deeper

Full BBOT analysis Full SCTX analysis Interactive comparison tool

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.